Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab in patients with acquired hemophilia A (Japan, Phase III)
jRCT2080225056Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of emicizumab in acquired haemophilia (AH), sponsored by Chugai Pharmaceutical Co., Ltd. Started Feb 2020; status: completed.
02
Drugs
emicizumab
03
Conditions
acquired haemophilia (AH)
Beyond the preview
Go deeper on jRCT2080225056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225056.